(Q36146900)

12 August 2017

1 reference

title

Disrupting tumour blood vessels (English)

1 reference

12 August 2017

1

Gillian M Tozer

1 reference

12 August 2017

Chryso Kanthou

2

1 reference

12 August 2017

Bruce C Baguley

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

published in

Nature Reviews Cancer

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

423-435

1 reference

Studies in tissue metabolism: The action of colchicine and B. typhosus extract

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Factors determining the action of colchicine on tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vinca alkaloids: anti-vascular effects in a murine tumour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antineoplastic agents, 122. Constituents of Combretum caffrum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antineoplastic agents. 379. Synthesis of phenstatin phosphate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

A new family of quinoline and quinoxaline analogues of combretastatins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Recent advances in the field of tubulin polymerization inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vascular occlusion and tumour cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Antivascular therapy of cancer: DMXAA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

The biology of the combretastatins as tumour vascular targeting agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Red blood cell behavior at low flow rate in microvessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Cytoskeletal regulation of pulmonary vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Regulation of vascular permeability by vascular endothelial growth factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Rho GTPases and the regulation of endothelial permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Myosin light-chain kinase of smooth muscle stimulates myosin ATPase activity without phosphorylating myosin light chain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Endothelial-cell proliferation in experimental tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Hypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Tumor necrosis factor-alpha-induced TRPC1 expression amplifies store-operated Ca2+ influx and endothelial permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Microvascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Role of Ca2+ signaling in the regulation of endothelial permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Cadherins as modulators of angiogenesis and the structural integrity of blood vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vascular targeting agents as cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Combretastatin A4 phosphate: background and current clinical status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Phase I trial of combretastatin a-4 phosphate with carboplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Delivery of molecular medicine to solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Synergy between vascular targeting agents and antibody-directed therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Tumor response to radiotherapy regulated by endothelial cell apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Targeting the tumor vasculature: a strategy to improve radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Openings between defective endothelial cells explain tumor vessel leakiness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Transport of molecules across tumor vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Causes and effects of heterogeneous perfusion in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Intracapillary oxyhemoglobin saturation of malignant tumors in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC1628

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1628

1 reference

Dimensions Publication ID

12 August 2017

1017276673

0 references

1 reference